Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.
Modus Therapeutics has raised $3.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2025.
Modus Therapeutics's investors include HealthCap, Karolinska, Rosetta Capital, Praktikerinvest, Ostersjöstiftelsen.
Modus Therapeutics is headquartered in Stockholm, Sweden.
Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.
Modus Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Modus Therapeutics — Funding & Investors." VCBacked, June 26, 2025, https://www.vcbacked.co/company/modus-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Modus Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/modus-therapeutics
{{cite web |title=Modus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/modus-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated